Atorvastatin exerts a preventive effect against steroid-induced necrosis of the femoral head by modulating Wnt5a release
- PMID: 38971901
- DOI: 10.1007/s00204-024-03817-z
Atorvastatin exerts a preventive effect against steroid-induced necrosis of the femoral head by modulating Wnt5a release
Abstract
Steroid-induced osteonecrosis of the femoral head (SONFH) is a prevalent form of osteonecrosis in young individuals. More efficacious clinical strategies must be used to prevent and treat this condition. One of the mechanisms through which SONFH operates is the disruption of normal differentiation in bone marrow adipocytes and osteoblasts due to prolonged and extensive use of glucocorticoids (GCs). In vitro, it was observed that atorvastatin (ATO) effectively suppressed the impact of dexamethasone (DEX) on bone marrow mesenchymal stem cells (BMSCs), specifically by augmenting their lipogenic differentiation while impeding their osteogenic differentiation. To investigate the underlying mechanisms further, we conducted transcriptome sequencing of BMSCs subjected to different treatments, leading to the identification of Wnt5a as a crucial gene regulated by ATO. The analyses showed that ATO exhibited the ability to enhance the expression of Wnt5a and modulate the MAPK pathway while regulating the Wnt canonical signaling pathway via the WNT5A/LRP5 pathway. Our experimental findings provide further evidence that the combined treatment of ATO and DEX effectively mitigates the effects of DEX, resulting in the upregulation of osteogenic genes (Runx2, Alpl, Tnfrsf11b, Ctnnb1, Col1a) and the downregulation of adipogenic genes (Pparg, Cebpb, Lpl), meanwhile leading to the upregulation of Wnt5a expression. So, this study offers valuable insights into the potential mechanism by which ATO can be utilized in the prevention of SONFH, thereby holding significant implications for the prevention and treatment of SONFH in clinical settings.
Keywords: Atorvastatin; Dexamethasone; LRP5; MAPK; SONFH; Wnt5a.
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
References
-
- Ahmadi A, Mazloomnejad R, Kasravi M et al (2022) Recent advances on small molecules in osteogenic differentiation of stem cells and the underlying signaling pathways. Stem Cell Res Ther 13(1):518. https://doi.org/10.1186/s13287-022-03204-4 - DOI - PubMed - PMC
-
- Bensreti H, Alhamad DW, Gonzalez AM et al (2023) Update on the role of glucocorticoid signaling in osteoblasts and bone marrow adipocytes during aging. Curr Osteoporos Rep 21(1):32–44. https://doi.org/10.1007/s11914-022-00772-5 - DOI - PubMed
-
- Cao H, Guan H, Lai Y, Qin L, Wang X (2016) Review of various treatment options and potential therapies for osteonecrosis of the femoral head. J Orthop Translat 4:57–70. https://doi.org/10.1016/j.jot.2015.09.005 - DOI - PubMed
-
- Chamani S, Liberale L, Mobasheri L et al (2021) The role of statins in the differentiation and function of bone cells. Eur J Clin Invest 51(7):e13534. https://doi.org/10.1111/eci.13534 - DOI - PubMed
-
- Chen J, Zhang C, Yan T et al (2021) Atorvastatin ameliorates early brain injury after subarachnoid hemorrhage via inhibition of pyroptosis and neuroinflammation. J Cell Physiol 236(10):6920–6931. https://doi.org/10.1002/jcp.30351 - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
